Moreover, with a handful of FDA-approved RAF/MEK inhibitors widely used in the clinic, the impact of inhibiting RAF and/or MEK on somatic tissue and tumor-infiltrating immune cells has recently been brought into the spotlight. This evidence concerns the gene RAF1 and neoplasm.